Proteomic analysis of the vitamin C effect on the doxorubicin cytotoxicity in the MCF-7 breast cancer cell line.
J Cancer Res Clin Oncol
; 143(1): 35-42, 2017 Jan.
Article
in En
| MEDLINE
| ID: mdl-27620743
ABSTRACT
PURPOSE:
Doxorubicin is an anthracycline drug which inhibits the growth of breast cancer cell lines. However, a major factor limiting its use is a cumulative, dose-dependent cardiotoxicity, resulting in a permanent loss of cardiomyocytes. Vitamin C was found to potentiate the cytotoxic effects of a variety of chemotherapeutic drugs including doxorubicin. The aim of the study was to describe the changes in protein expression and proliferation of the MCF-7 cells induced by the vitamin C applied with doxorubicin.METHODS:
Label-free quantitative proteomics and real-time cell analysis methods were used to search for proteome and cell proliferation changes. These changes were induced by the pure DOX and by DOX combined with vitamin C applied on the MCF-7 cell line.RESULTS:
From the real-time cell analysis experiments, it is clear that the highest anti-proliferative effect occurs with the addition of 200 µM of vitamin C to 1 µM of doxorubicin. By applying both the label-free protein quantification method and total ion current assay, we found statistically significant changes (p ≤ 0.05) of 26 proteins induced by the addition of vitamin C to doxorubicin on the MCF-7 cell line. These differentially expressed proteins are involved in processes such as structural molecule activity, transcription and translation, immune system process and antioxidant, cellular signalling and transport.CONCLUSION:
The detected proteins may be capable of predicting response to DOX therapy. This is a key tool in the treatment of breast cancer, and the combination with vit C seems to be of particular interest due to the fact that it can potentiate anti-proliferative effect of DOX.Key words
Full text:
1
Database:
MEDLINE
Main subject:
Ascorbic Acid
/
Breast Neoplasms
/
Doxorubicin
/
Proteome
/
Antibiotics, Antineoplastic
Type of study:
Prognostic_studies
Limits:
Female
/
Humans
Language:
En
Journal:
J Cancer Res Clin Oncol
Year:
2017
Type:
Article
Affiliation country:
Slovakia